Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement.
Lebwohl M, Bukhalo M, Stein Gold L, Glick B, Llamas-Velasco M, Sanchez-Rivera S, Pan A, Zhan T, Drogaris L, Douglas K, St John G, Espaillat R, Bissonnette R. Lebwohl M, et al. Among authors: sanchez rivera s. J Am Acad Dermatol. 2024 Dec;91(6):1150-1157. doi: 10.1016/j.jaad.2024.07.1521. Epub 2024 Aug 30. J Am Acad Dermatol. 2024. PMID: 39208985 Free article. Clinical Trial.
Evaluation of Genotoxic Effect and Antigenotoxic Potential against DNA Damage of the Aqueous and Ethanolic Leaf Extracts of Annona muricata Using an In Vivo Erythrocyte Rodent Micronucleus Assay.
Sánchez-De-La-Rosa SV, Lazalde-Ramos BP, Morales-Velazquez G, Zúñiga-González GM, Gómez-Meda BC, Sánchez-Rivera SO, Ortiz-García YM, Guerrero-Velazquez C, Zamora-Perez AL. Sánchez-De-La-Rosa SV, et al. Among authors: sanchez rivera so. Biomed Res Int. 2022 Dec 16;2022:9554011. doi: 10.1155/2022/9554011. eCollection 2022. Biomed Res Int. 2022. PMID: 36567911 Free PMC article.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. Blauvelt A, et al. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15. Br J Dermatol. 2020. PMID: 31887225 Free PMC article. Clinical Trial.